Targeting the E2F1/GAS5/p53 Axis as a Potential Therapeutic Strategy for Gefitinib-Resistant Lung Cancer
碩士 === 國立臺灣大學 === 分子與細胞生物學研究所 === 106 === Lung cancer is one of the most common and fatal cancer worldwide. There are two major types of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Recently, gefitinib, a small molecule, which target tyrosine kinase, has been re...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en_US |
| Published: |
2018
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/sdq5ze |